Preview: Merck’s Animal Health business generated $1.775 billion in second-quarter 2026 sales, driven by growth across both livestock and companion animal portfolios, while the company also completed its acquisition of poultry technology company TARGAN.
- Merck Animal Health reported $1.775 billion in second-quarter sales, an 8% increase year over year (5% excluding foreign exchange).
- Livestock sales increased 8% to $1.041 billion, supported by higher demand for ruminant and poultry products.
- Companion Animal sales rose 7% to $734 million, driven by new product launches.
- Sales of the BRAVECTO portfolio reached $359 million, up 7% from the prior-year quarter.
- Merck Animal Health also completed its acquisition of TARGAN, expanding its poultry portfolio with automated in-ovo delivery technology.
Merck & Co. reported second-quarter 2026 worldwide sales of $16.6 billion, a 5% increase from the prior year, with Animal Health contributing $1.775 billion in revenue during the quarter. The company said Animal Health sales grew 8% year over year, or 5% excluding the impact of foreign exchange.
Livestock and companion animal portfolios both post growth
The Livestock business generated $1.041 billion in sales, up 8%, reflecting higher demand for ruminant and poultry products.
Companion Animal revenue reached $734 million, an increase of 7%, which Merck attributed primarily to new product launches. Within the portfolio, sales of the BRAVECTO line totaled $359 million, compared with $335 million during the same quarter last year.
Poultry portfolio expands with TARGAN acquisition
Merck Animal Health completed its acquisition of TARGAN, adding the company’s high-speed automated biodevice technology to its commercial poultry portfolio.
Company raises full-year sales outlook
Merck increased and narrowed its full-year 2026 worldwide sales guidance to $66.3 billion to $67.3 billion, compared with its previous outlook of $65.8 billion to $67.0 billion.
Full earnings report: https://www.merck.com/news/
Information sourced from Merck & Co.’s second-quarter 2026 earnings release.
Forward-looking statements: This article summarizes information from Merck’s earnings release, which contains forward-looking statements regarding future financial performance, business strategy, product development, regulatory milestones, and market expectations. Actual results may differ materially due to risks and uncertainties described in the company’s SEC filings and the complete earnings report.
